Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novo Nordisk
Novo Nordisk
Lilly Edges Out J&J to Top 20 BioPharma Market Cap List for 2023
BioSpace
Tue, 02/20/24 - 05:55 pm
market cap
Eli Lilly
JNJ
Novo Nordisk
Novo Nordisk and Catalent deal: net positive or negative for industry?
Biopharma Reporter
Tue, 02/20/24 - 11:06 am
Novo Nordisk
Catalent
M&A
Wegovy
Ozempic
Wegovy fuels sharp rise in use of weight-loss drugs for US youth
Reuters
Thu, 02/15/24 - 07:24 pm
Wegovy
Novo Nordisk
pediatric
Weight loss drugs like Ozempic have food CEOs so 'scared' they're calling Novo Nordisk for advice
Quartz
Thu, 02/15/24 - 07:20 pm
Novo Nordisk
Lars Fruergaard Jorgensen
Ozempic
Wegovy
weight loss
3 questions hanging over the Novo-Catalent deal
Pharma Voice
Wed, 02/14/24 - 10:55 am
Novo Nordisk
Catalent
drug manufacturing
Ozempic Wegovy
Eli Lilly
Novo Nordisk's controlling shareholder plans to invest about $35 bln by 2030
Reuters
Mon, 02/12/24 - 11:19 pm
Novo Nordisk
Novo Holdings
Weight-loss drugs tied to benefit after hip replacement
Reuters
Mon, 02/12/24 - 10:26 am
hip replacements
GLP-1 agonist
Ozempic
Novo Nordisk
COVID-19 Cliff and Skyrocketing GLP-1 Drug Sales Highlight Q4 2023 Earnings
BioSpace
Sun, 02/11/24 - 03:50 pm
earnings
COVID-19
GLP-1 agonist
JNJ
Bristol Myers Squibb
Pfizer
AstraZeneca
Sanofi
Eli Lilly
Novo Nordisk
As Catalent prepares to join Novo family, CDMO's sales continue to slide
Fierce Pharma
Fri, 02/9/24 - 11:21 am
Catalent
CDMOs
earnings
Novo Nordisk
New weight-loss drugs linked to lower risk of depression: study
Axios
Fri, 02/9/24 - 11:12 am
depression
weight loss
Novo Nordisk
Eli Lilly
Ozempic
Wegovy
Mounjaro
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
Motley Fool
Thu, 02/8/24 - 10:01 pm
Merck
Eli Lilly
Novo Nordisk
weight loss
Novo Nordisk CEO Jørgensen nets a 13% raise for 2023 amid soaring demand for Wegovy, Ozempic
Fierce Pharma
Wed, 02/7/24 - 09:15 pm
Novo Nordisk
executive pay
Lars Fruergaard Jorgensen
Pharma CEOs
FDA finds control lapses at Catalent plant being sold to Novo
Reuters
Tue, 02/6/24 - 11:36 pm
FDA
drug manufacturing
regulatory
Novo Nordisk
Catalent
Eli Lilly mounts clinical and commercial case for tirzepatide as Mounjaro, Zepbound chalk up major gains
Fierce Pharma
Tue, 02/6/24 - 09:33 am
Eli Lilly
tirzepatide
Novo Nordisk
Zepbound
Mounjaro
Novo Holdings acquires Catalent in $16.5B deal, aiming to boost Wegovy production as demand soars
Medical Marketing and Media
Mon, 02/5/24 - 11:06 pm
Novo Nordisk
Catalent
drug manufacturing
Wegovy
M&A
Could Novo, Lilly become first trillion-dollar healthcare companies?
Pharma Voice
Mon, 02/5/24 - 10:30 am
Novo Nordisk
Eli Lilly
Ozempic
Wegovy
Mounjaro
obesity
weight loss
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
CNBC
Mon, 02/5/24 - 10:10 am
Novo Nordisk
Catalent
drug manufacturing
M&A
Wegovy
Ozempic
Could Abbott Labs Be the Next Big Winner in the Billion-Dollar Weight Loss Market?
Motley Fool
Fri, 02/2/24 - 11:50 am
Abbott Labs
Novo Nordisk
Eli Lilly
weight loss
Protality
Novo Nordisk doubles stock of Wegovy starter doses but supply constraints persist: CEO
Fierce Pharma
Wed, 01/31/24 - 11:56 am
Novo Nordisk
Wegovey
earnings
Ozempic
Novo Nordisk R&D spend jumps 35% thanks to soaring sales as oral obesity plans advance
Fierce Biotech
Wed, 01/31/24 - 11:55 am
Novo Nordisk
R&D
obesity
amycretin
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »